Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00493155 · ClinicalTrials.gov registry record · Phase 1
A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00493155 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 48 participants.
The verdict
NCT00493155, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This study will determine the maximum tolerated dose, and assess the safety, tolerability and pharmacokinetics of R1530 administered orally to patients with advanced or metastatic solid tumors. R1530 will be administered daily for 14 days at the starting dose; this dose will be escalated in subsequent cohorts of patients, after a satisfactory assessment of safety and tolerability of the previous dose, until the maximum tolerated dose is reached. The anticipated time on study treatment is until disease progression, and the target sample size is \<100 individuals.
Interventions
- DRUG RG1530
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2005-10 |
| Est. Completion | 2009-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00493155
The ClinicalTrials.gov registry entry for NCT00493155 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RG1530 is the first listed.
NCT00493155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00493155 about?
NCT00493155 is a clinical study titled "A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.". This study will determine the maximum tolerated dose, and assess the safety, tolerability and pharmacokinetics of R1530 administered orally to patients with advanced or metastatic solid tumors. R1530 will be administered daily for 14 days at the starting dose; this dose will be escalated in subseque...
What is the current status of trial NCT00493155?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2005-10. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00493155?
The interventions under investigation include: RG1530 (DRUG).
Who is sponsoring clinical trial NCT00493155?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.